Experience with low-dose replacement therapy in the initial management of severe pediatric acquired primary...

Area of Science:

• Pediatric Endocrinology
• Hormone Replacement Therapy
• Child Development

Background:

• Severe primary hypothyroidism in children often leads to behavioral issues like irritability and poor concentration with rapid hormonal replacement.
• Concerns exist that standard treatment regimens may negatively impact growth velocity.

Purpose of the Study:

• To evaluate the efficacy of an incremental, low-dose thyroxine (T4) treatment regimen in managing severe primary hypothyroidism in children and adolescents.
• To assess the impact of this gradual T4 replacement on growth velocity and overall development.
• To determine the optimal T4 dosage for achieving euthyroidism without compromising growth.

Main Methods:

• A retrospective review of 14 children and adolescents treated with a gradual incremental thyroxine (T4) dosage over 4.5 to 6 months.
• Analysis of growth velocity and growth z-scores for patients with remaining growth potential.
• Determination of the thyroxine (T4) dose required to normalize thyroid-stimulating hormone (TSH) levels.

Main Results:

• For 10 patients with growth potential, 5-7 month growth velocity was 8.5 +/- 1.9 cm/year (z-score 1.5 +/- 1.7), indicating satisfactory growth.
• The thyroxine (T4) dose to normalize TSH was lower than previously suggested, averaging 1.6 +/- 0.74 microgram/kg.
• The regimen effectively alleviated behavioral symptoms associated with hypothyroidism.

Conclusions:

• Gradual, incremental thyroxine (T4) replacement therapy is effective in treating severe primary hypothyroidism in children.
• This approach supports satisfactory growth velocity and development, even with biochemical hypothyroidism.
• Lower thyroxine (T4) doses than previously proposed may be sufficient for initial euthyroidism.